Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C1-esterase inhibitor for refractory antibody-mediated rejection in adult kidney transplant recipients
2017-000348-17Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in humoral rejection and kidney allograft rejection comparing C1-esterase inhibitor + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to loss of response during Treatment Period 2. Started Apr 2017; status: completed.
02
Drugs
cinryze
03
Conditions
humoral rejectionkidney allograft rejection
Beyond the preview
Go deeper on 2017-000348-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000348-17.